Holen Sie sich die Stockscreener-App
68.94
3.30%
2.20
Vorhandelsmarkt:
69.02
0.08
+0.12%
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
Structure Therapeutics Announces $650 Million Public Offering - TipRanks
Structure Therapeutics’ Leap: What’s Sparking the Surge? - StocksToTrade
Structure Therapeutics Shares Surge on Promising Drug Results - TipRanks
Structure Therapeutics Inc. (GPCR) Stock: Skyrockets After Positive Obesity Trial Result - Menafn
Structure Therapeutics prices upsized $650 million public offering By Investing.com - Investing.com South Africa
Structure Therapeutics prices upsized $650 million public offering - Investing.com
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants - GlobeNewswire Inc.
Structure Therapeutics Inc. (GPCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial - Finviz
Discipline and Rules-Based Execution in GPCR Response - news.stocktradersdaily.com
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook - ts2.tech
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron - Yahoo Finance
This trade activity should not be overlooked: Structure Therapeutics Inc ADR (GPCR) - Setenews
Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More - ts2.tech
Structure Therapeutics stock hits 52-week high at 45.05 USD By Investing.com - Investing.com Canada
Why Structure Therapeutics Stock Doubled and Then Some on Monday - Finviz
Structure Therapeutics Unveils Major Data Release Driving Market Buzz - StocksToTrade
Structure Therapeutics stock price target raised to $90 by Stifel - Investing.com
Mid Cap Stocks To Watch TodayDecember 8th - MarketBeat
Structure Therapeutics stock falls after $500 million share offering - Investing.com India
Structure Therapeutics launches $500 million public offering By Investing.com - Investing.com South Africa
Structure Therapeutics (NASDAQ: GPCR) plans $500M ADS sale with $75M option - Stock Titan
2 companies poised to capitalize on the rise of GLP-1 drugs - Morningstar Australia
Structure Therapeutics’ Potential Breakthrough: Market Awaits Data - StocksToTrade
Pharmaceutical Stocks To Follow TodayDecember 8th - MarketBeat
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Promising Potential of Structure Therapeutics’ Aleniglipron: A Buy Rating Based on Transformative Efficacy and Strategic Innovation - TipRanks
Positive Outlook for Structure Therapeutics: Aleniglipron Shows Promising Results in Obesity Treatment - TipRanks
Structure Phase 2 data for aleniglipron look ‘competitive,’ says Morgan Stanley - TipRanks
Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill - The Wall Street Journal
Structure Therapeutics posts mid-stage weight-loss pill data in line with Eli Lilly rival - Sherwood News
Structure Therapeutics stock hits 52-week high at 45.05 USD - Investing.com
Structure Therapeutics Announces Positive Clinical Trial Results - TipRanks
Structure Therapeutics stock soars after strong weight loss data for oral drug - Investing.com UK
Biotech Soars On Potential 'Best-In-Class' Obesity Drug - Investor's Business Daily
Structure Therapeutics’ Stocks Surge on Promising Drug Data - TipRanks
GPCR: Aleniglipron achieved up to 15.3% weight loss at 36 weeks with strong safety and no plateau - TradingView
GPCR: Aleniglipron showed up to 15.3% weight loss at 36 weeks with strong safety and tolerability - TradingView
Structure Therapeutics (NASDAQ: GPCR) oral GLP-1 cuts weight up to 15.3% in Phase 2 data - Stock Titan
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 - The Manila Times
Structure Therapeutics Inc. to Announce Topline Data from ACCESS Clinical Program for Aleniglipron on December 8, 2025 - Quiver Quantitative
Structure Therapeutics (NASDAQ: GPCR) to unveil ACCESS obesity program data, host call Dec. 8 - Stock Titan
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by Capital Fund Management S.A. - Defense World
American Century Companies Inc. Cuts Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 5.5%Here's Why - MarketBeat
Taking the lead: Structure Therapeutics Inc ADR (GPCR) - Setenews
BARK Inc (BARK) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
9th Circ. Mulls Pharma Exec's Use Of Forced Arbitration Law - Law360
Structure Therapeutics stock: Stifel reiterates Buy rating ahead of key data - Investing.com
Envestnet Asset Management Inc. Buys Shares of 10,676 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Endava PLC Sponsored ADR (NYSE:DAVA) Given Consensus Rating of “Hold” by Analysts - Defense World
Tejara Capital Ltd Acquires New Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Behavioral Patterns of GPCR and Institutional Flows - news.stocktradersdaily.com
10,635 Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR Acquired by DNB Asset Management AS - MarketBeat
Rhenman & Partners Asset Management AB Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
5 Argument Sessions Bias Attys Should Watch In Dec. - Law360
A better buy-in window may exist right now for Structure Therapeutics Inc ADR (GPCR) - Setenews
Promising Potential of Structure Therapeutics’ Aleniglipron in the Incretin-Based Therapy Landscape - TipRanks
DCF Advisers LLC Makes New Investment in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Buy Rating for Structure Therapeutics, Inc.: Potential Disruption in Obesity Treatment with Amylin Agonists - TipRanks
Calif. Forecast: Tribe To Make Sovereignty Args In Labor Suit - Law360
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):